Concepts (145)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Epitopes, T-Lymphocyte | 6 | 2024 | 824 | 1.860 |
Why?
|
CD8-Positive T-Lymphocytes | 13 | 2024 | 4550 | 1.540 |
Why?
|
AIDS Vaccines | 4 | 2023 | 895 | 1.200 |
Why?
|
HLA-B Antigens | 3 | 2024 | 331 | 1.040 |
Why?
|
HIV-1 | 11 | 2024 | 6849 | 0.900 |
Why?
|
HIV Infections | 14 | 2024 | 17165 | 0.770 |
Why?
|
Immunodominant Epitopes | 1 | 2021 | 241 | 0.710 |
Why?
|
T-Lymphocytes, Cytotoxic | 4 | 2023 | 1765 | 0.630 |
Why?
|
Acquired Immunodeficiency Syndrome | 2 | 2019 | 2197 | 0.600 |
Why?
|
Histocompatibility Antigens Class I | 2 | 2021 | 1355 | 0.580 |
Why?
|
Receptors, Antigen, T-Cell | 2 | 2024 | 2536 | 0.520 |
Why?
|
Peptides | 5 | 2024 | 4354 | 0.490 |
Why?
|
CD4-Positive T-Lymphocytes | 8 | 2024 | 4353 | 0.480 |
Why?
|
HIV | 2 | 2014 | 1579 | 0.470 |
Why?
|
Caspase 8 | 1 | 2014 | 188 | 0.470 |
Why?
|
Protein Binding | 3 | 2024 | 9335 | 0.440 |
Why?
|
Caspase 1 | 1 | 2014 | 226 | 0.430 |
Why?
|
Protein Stability | 2 | 2024 | 566 | 0.370 |
Why?
|
Pulmonary Surfactant-Associated Protein A | 1 | 2008 | 31 | 0.320 |
Why?
|
DNA, Viral | 1 | 2014 | 2194 | 0.280 |
Why?
|
Dendritic Cells | 3 | 2021 | 2725 | 0.270 |
Why?
|
Phosphoproteins | 1 | 2014 | 2440 | 0.240 |
Why?
|
Receptors, KIR3DL1 | 1 | 2024 | 27 | 0.240 |
Why?
|
Nuclear Proteins | 3 | 2014 | 5795 | 0.210 |
Why?
|
Viremia | 2 | 2023 | 707 | 0.200 |
Why?
|
Protein Denaturation | 1 | 2021 | 242 | 0.190 |
Why?
|
Vaccination | 2 | 2023 | 3359 | 0.190 |
Why?
|
Alleles | 3 | 2021 | 6900 | 0.180 |
Why?
|
Host-Pathogen Interactions | 3 | 2021 | 1447 | 0.180 |
Why?
|
Virus Replication | 3 | 2019 | 2432 | 0.180 |
Why?
|
Conserved Sequence | 2 | 2021 | 1167 | 0.160 |
Why?
|
Mass Vaccination | 1 | 2020 | 109 | 0.160 |
Why?
|
Antiphospholipid Syndrome | 1 | 2020 | 165 | 0.160 |
Why?
|
HLA Antigens | 2 | 2021 | 1368 | 0.160 |
Why?
|
Surface Properties | 1 | 2021 | 1161 | 0.150 |
Why?
|
gag Gene Products, Human Immunodeficiency Virus | 1 | 2019 | 206 | 0.150 |
Why?
|
HIV Seropositivity | 1 | 2023 | 955 | 0.150 |
Why?
|
Apoptosis | 1 | 2014 | 9497 | 0.150 |
Why?
|
HEK293 Cells | 3 | 2021 | 4263 | 0.130 |
Why?
|
Binding Sites | 1 | 2024 | 6048 | 0.130 |
Why?
|
Immunocompromised Host | 1 | 2020 | 857 | 0.120 |
Why?
|
HIV Core Protein p24 | 1 | 2014 | 245 | 0.120 |
Why?
|
Humans | 28 | 2024 | 760613 | 0.120 |
Why?
|
Viral Load | 3 | 2023 | 3322 | 0.120 |
Why?
|
Models, Molecular | 1 | 2024 | 5434 | 0.110 |
Why?
|
Receptor-Interacting Protein Serine-Threonine Kinases | 1 | 2014 | 140 | 0.110 |
Why?
|
Flow Cytometry | 1 | 2024 | 5869 | 0.110 |
Why?
|
Polymorphism, Genetic | 1 | 2024 | 4286 | 0.110 |
Why?
|
Pulmonary Surfactant-Associated Protein D | 1 | 2013 | 48 | 0.110 |
Why?
|
Antibodies, Viral | 1 | 2023 | 3142 | 0.100 |
Why?
|
Vaccines | 1 | 2020 | 832 | 0.100 |
Why?
|
Necrosis | 1 | 2014 | 1612 | 0.090 |
Why?
|
Proteome | 1 | 2019 | 1855 | 0.080 |
Why?
|
Enzyme Activation | 1 | 2014 | 3602 | 0.080 |
Why?
|
High-Throughput Screening Assays | 1 | 2014 | 944 | 0.080 |
Why?
|
RNA Interference | 2 | 2014 | 2846 | 0.080 |
Why?
|
Interferon-beta | 1 | 2010 | 345 | 0.080 |
Why?
|
Cytosol | 1 | 2011 | 887 | 0.080 |
Why?
|
RNA, Small Interfering | 2 | 2014 | 3442 | 0.080 |
Why?
|
Mannose | 1 | 2008 | 121 | 0.080 |
Why?
|
HIV Envelope Protein gp120 | 2 | 2013 | 915 | 0.080 |
Why?
|
Influenza A virus | 1 | 2011 | 457 | 0.070 |
Why?
|
Antiretroviral Therapy, Highly Active | 1 | 2016 | 1894 | 0.070 |
Why?
|
Virus Internalization | 1 | 2011 | 494 | 0.070 |
Why?
|
Jurkat Cells | 3 | 2014 | 736 | 0.070 |
Why?
|
RNA-Binding Proteins | 2 | 2014 | 1894 | 0.070 |
Why?
|
Interferon-alpha | 1 | 2010 | 919 | 0.070 |
Why?
|
Oligosaccharides | 1 | 2008 | 405 | 0.070 |
Why?
|
Cricetinae | 1 | 2008 | 2427 | 0.060 |
Why?
|
Nucleocapsid | 1 | 2024 | 63 | 0.060 |
Why?
|
Animals | 6 | 2024 | 167960 | 0.060 |
Why?
|
Hydrogen-Ion Concentration | 1 | 2008 | 2502 | 0.060 |
Why?
|
Interferon-gamma | 1 | 2011 | 3157 | 0.050 |
Why?
|
HeLa Cells | 3 | 2014 | 3105 | 0.050 |
Why?
|
Proviruses | 1 | 2023 | 313 | 0.050 |
Why?
|
Peptide Fragments | 1 | 2014 | 5132 | 0.050 |
Why?
|
Cells, Cultured | 2 | 2014 | 18955 | 0.050 |
Why?
|
Antibodies, Neutralizing | 2 | 2023 | 1933 | 0.050 |
Why?
|
Cell Line | 3 | 2013 | 15620 | 0.050 |
Why?
|
CD4-CD8 Ratio | 1 | 2021 | 114 | 0.050 |
Why?
|
Anti-HIV Agents | 1 | 2016 | 4491 | 0.040 |
Why?
|
Cytotoxicity, Immunologic | 1 | 2024 | 1351 | 0.040 |
Why?
|
Influenza, Human | 1 | 2011 | 1528 | 0.040 |
Why?
|
Histocompatibility Antigens Class II | 1 | 2024 | 1446 | 0.040 |
Why?
|
Repressor Proteins | 1 | 2010 | 2982 | 0.040 |
Why?
|
Vaccines, Synthetic | 1 | 2022 | 617 | 0.040 |
Why?
|
Cell Proliferation | 1 | 2014 | 10442 | 0.040 |
Why?
|
Antigens | 1 | 2024 | 1447 | 0.040 |
Why?
|
Recombinant Proteins | 1 | 2008 | 6538 | 0.040 |
Why?
|
Antiviral Agents | 1 | 2010 | 3061 | 0.040 |
Why?
|
Disease Progression | 1 | 2014 | 13505 | 0.040 |
Why?
|
Adoptive Transfer | 1 | 2020 | 822 | 0.040 |
Why?
|
RNA, Messenger | 2 | 2023 | 12762 | 0.030 |
Why?
|
Gene Expression Regulation | 1 | 2014 | 11902 | 0.030 |
Why?
|
Epitopes | 1 | 2023 | 2503 | 0.030 |
Why?
|
Kinetics | 1 | 2024 | 6377 | 0.030 |
Why?
|
Fatal Outcome | 1 | 2020 | 1832 | 0.030 |
Why?
|
Immunophenotyping | 1 | 2021 | 1870 | 0.030 |
Why?
|
Immunization | 1 | 2020 | 1227 | 0.030 |
Why?
|
T-Lymphocytes | 1 | 2013 | 10181 | 0.030 |
Why?
|
RNA, Viral | 1 | 2023 | 2838 | 0.030 |
Why?
|
CD4 Lymphocyte Count | 1 | 2021 | 2569 | 0.030 |
Why?
|
Membrane Proteins | 1 | 2011 | 7850 | 0.030 |
Why?
|
Mutation | 1 | 2019 | 29957 | 0.030 |
Why?
|
Immunity, Cellular | 1 | 2020 | 1557 | 0.030 |
Why?
|
T-Lymphocyte Subsets | 1 | 2022 | 1810 | 0.030 |
Why?
|
Hexoses | 1 | 2013 | 29 | 0.030 |
Why?
|
Agglutination | 1 | 2013 | 41 | 0.030 |
Why?
|
Phorbol Esters | 1 | 2012 | 108 | 0.030 |
Why?
|
Adaptor Proteins, Vesicular Transport | 1 | 2014 | 306 | 0.030 |
Why?
|
Transcription Factors | 1 | 2012 | 12102 | 0.030 |
Why?
|
tat Gene Products, Human Immunodeficiency Virus | 1 | 2012 | 119 | 0.030 |
Why?
|
Administration, Oral | 1 | 2020 | 4035 | 0.030 |
Why?
|
Cell Cycle Proteins | 2 | 2014 | 3448 | 0.020 |
Why?
|
Binding, Competitive | 1 | 2013 | 1142 | 0.020 |
Why?
|
Male | 5 | 2023 | 359718 | 0.020 |
Why?
|
Virus Activation | 1 | 2012 | 319 | 0.020 |
Why?
|
Azepines | 1 | 2012 | 330 | 0.020 |
Why?
|
Mice, Transgenic | 1 | 2023 | 9530 | 0.020 |
Why?
|
Anti-Retroviral Agents | 1 | 2020 | 1779 | 0.020 |
Why?
|
Female | 4 | 2023 | 391246 | 0.020 |
Why?
|
Virus Latency | 1 | 2012 | 362 | 0.020 |
Why?
|
Minor Histocompatibility Antigens | 1 | 2010 | 293 | 0.020 |
Why?
|
Chickens | 1 | 2011 | 860 | 0.020 |
Why?
|
Recurrence | 1 | 2021 | 8483 | 0.020 |
Why?
|
Amino Acid Sequence | 1 | 2021 | 13451 | 0.020 |
Why?
|
Adult | 4 | 2022 | 220007 | 0.020 |
Why?
|
Biological Transport | 1 | 2013 | 2086 | 0.020 |
Why?
|
Prospective Studies | 2 | 2024 | 54306 | 0.020 |
Why?
|
Triazoles | 1 | 2012 | 904 | 0.020 |
Why?
|
DNA | 1 | 2020 | 7233 | 0.020 |
Why?
|
Mice | 2 | 2024 | 81209 | 0.020 |
Why?
|
GTP-Binding Proteins | 1 | 2010 | 951 | 0.020 |
Why?
|
Genotype | 1 | 2021 | 12957 | 0.020 |
Why?
|
Leukocytes, Mononuclear | 1 | 2010 | 1827 | 0.010 |
Why?
|
Lung | 1 | 2022 | 9994 | 0.010 |
Why?
|
Middle Aged | 3 | 2021 | 220359 | 0.010 |
Why?
|
Carrier Proteins | 1 | 2014 | 4938 | 0.010 |
Why?
|
Pandemics | 1 | 2020 | 8623 | 0.010 |
Why?
|
Adolescent | 1 | 2008 | 87809 | 0.010 |
Why?
|
Gene Expression | 1 | 2012 | 7587 | 0.010 |
Why?
|
Lymphocyte Activation | 1 | 2010 | 5496 | 0.010 |
Why?
|
DNA-Binding Proteins | 1 | 2014 | 9591 | 0.010 |
Why?
|
Algorithms | 1 | 2014 | 13982 | 0.010 |
Why?
|
Cohort Studies | 1 | 2010 | 41337 | 0.000 |
Why?
|
Concepts
(145)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(68)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_
Same Department
People in same department with this person.
Explore
_